Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (25)

« Back to Publications

Systemic Lupus Erythematosus With Cardiac Tamponade and Myocardial Edema in the Early Postpartum Period.

Shabbir A. et al, (2025), JACC Case Rep, 30

Type 1 interferons: A target for Immune-mediated inflammatory diseases (IMIDs)

Mathian A. et al, (2025), Revue du Rhumatisme (Edition Francaise)

Blood RNA-sequencing across the continuum of ANA-positive autoimmunity reveals insights into initiating immunopathology.

Carter LM. et al, (2024), Ann Rheum Dis, 83, 1322 - 1334

Editorial: New insights into interferons and proinflammatory cytokines in lupus

White WI. et al, (2024), Frontiers in Lupus, 2

Type 1 interferons: A target for immune-mediated inflammatory diseases (IMIDs).

Mathian A. et al, (2024), Joint Bone Spine, 91

Gene Expression and Autoantibody Analysis Revealing Distinct Ancestry-Specific Profiles Associated With Response to Rituximab in Refractory Systemic Lupus Erythematosus.

Carter LM. et al, (2023), Arthritis Rheumatol, 75, 697 - 710

cellular overview of immunometabolism in systemic lupus erythematosus.

Psarras A. and Clarke A., (2023), Oxf Open Immunol, 4

Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope.

Md Yusof MY. et al, (2023), Rheumatol Adv Pract, 7

Novel La1−xCaxMnO3 perovskite materials for chemical looping combustion applications

Iliopoulou EF. et al, (2022), International Journal of Energy Research, 46, 20386 - 20400

nti-BDCA2 Antibody for Cutaneous Lupus Erythematosus.

Psarras A. and Vital EM., (2022), N Engl J Med, 387, 1528 - 1529

Emerging concepts of type I interferons in SLE pathogenesis and therapy.

Psarras A. et al, (2022), Nat Rev Rheumatol, 18, 575 - 590

Keratinocytes: From passive targets to active mediators of systemic autoimmunity.

Psarras A. and Vital EM., (2022), Sci Transl Med, 14

TNF-α Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN-α Production and Enhancing T Cell Activation.

Psarras A. et al, (2021), J Immunol, 206, 785 - 796

Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity.

Psarras A. et al, (2020), Nat Commun, 11

B Cell Tetherin: A Flow Cytometric Cell-Specific Assay for Response to Type I Interferon Predicts Clinical Features and Flares in Systemic Lupus Erythematosus.

El-Sherbiny YM. et al, (2020), Arthritis Rheumatol, 72, 769 - 779

Load More